SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 148.58 Billion KRW | -62.88% |
| 2022 | 400.22 Billion KRW | -21.34% |
| 2021 | 508.81 Billion KRW | 70.49% |
| 2020 | 298.44 Billion KRW | 74.28% |
| 2019 | 171.24 Billion KRW | -10.8% |
| 2018 | 191.98 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 228.61 Billion KRW | 0.93% |
| 2024 Q1 | 226.51 Billion KRW | 52.45% |
| 2023 Q1 | 294.73 Billion KRW | -26.36% |
| 2023 FY | 148.58 Billion KRW | -62.88% |
| 2023 Q4 | 148.58 Billion KRW | -24.67% |
| 2023 Q3 | 197.23 Billion KRW | -23.29% |
| 2023 Q2 | 257.12 Billion KRW | -12.76% |
| 2022 Q3 | 390.74 Billion KRW | -3.84% |
| 2022 Q2 | 406.36 Billion KRW | 10.49% |
| 2022 Q1 | 367.79 Billion KRW | -27.72% |
| 2022 FY | 400.22 Billion KRW | -21.34% |
| 2022 Q4 | 400.22 Billion KRW | 2.43% |
| 2021 Q4 | 508.81 Billion KRW | 1.98% |
| 2021 Q2 | 448.27 Billion KRW | 6.89% |
| 2021 Q3 | 498.93 Billion KRW | 11.3% |
| 2021 FY | 508.81 Billion KRW | 70.49% |
| 2021 Q1 | 419.37 Billion KRW | 40.52% |
| 2020 Q2 | 187.82 Billion KRW | 7.45% |
| 2020 FY | 298.44 Billion KRW | 74.28% |
| 2020 Q4 | 298.44 Billion KRW | 9.56% |
| 2020 Q3 | 272.39 Billion KRW | 45.03% |
| 2020 Q1 | 174.79 Billion KRW | 2.07% |
| 2019 Q2 | 185.44 Billion KRW | -3.11% |
| 2019 FY | 171.24 Billion KRW | -10.8% |
| 2019 Q3 | 175.85 Billion KRW | -5.17% |
| 2019 Q4 | 171.24 Billion KRW | -2.62% |
| 2019 Q1 | 191.4 Billion KRW | -0.3% |
| 2018 Q4 | 191.98 Billion KRW | 2.11% |
| 2018 Q3 | 188.02 Billion KRW | 0.0% |
| 2018 FY | 191.98 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ORIENT BIO Inc. | 11.89 Billion KRW | -1149.464% |
| Green Cross Holdings Corporation | 1856.16 Billion KRW | 91.995% |
| Green Cross Holdings Corporation | 1103.45 Billion KRW | 86.535% |
| Pharmicell Co., Ltd. | 18.79 Billion KRW | -690.578% |
| Green Cross Corporation | 1103.45 Billion KRW | 86.535% |
| GeneOne Life Science, Inc. | 39.51 Billion KRW | -275.986% |
| Celltrion, Inc. | 2791.73 Billion KRW | 94.678% |
| Samsung Biologics Co.,Ltd. | 6215.7 Billion KRW | 97.61% |
| SK Biopharmaceuticals Co., Ltd. | 402.21 Billion KRW | 63.059% |
| Prestige BioPharma Limited | 196.21 Billion KRW | 24.276% |